Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H25NO2S |
Molecular Weight | 355.494 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(SC)=CC=C1C(=O)N2CCC(CC3=CC=CC=C3)CC2
InChI
InChIKey=OMGLGPKQUFSRNN-UHFFFAOYSA-N
InChI=1S/C21H25NO2S/c1-24-20-15-18(25-2)8-9-19(20)21(23)22-12-10-17(11-13-22)14-16-6-4-3-5-7-16/h3-9,15,17H,10-14H2,1-2H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16847144Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2012154814A1 | https://encrypted.google.com/patents/WO2006018842A3
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16847144
Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2012154814A1 | https://encrypted.google.com/patents/WO2006018842A3
JX-401 is potent, reversible inhibitor of p38α that displays no activity on the p38γ isoform. JX-401 is effective in mammalian cells, as it blocks the differentiation of myoblasts into myotubes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16847144 |
32.2 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16847144
L8 myoblasts were grown in growth medium (15% bovine calf serum in Dulbecco’s modified Eagle’s medium). For induction of differentiation, the medium was changed to differentiation medium (no serum, 10 mkg/ml insulin, and transferrin in Dulbecco’s modified Eagle’s medium) when the culture became confluent. JX401, and its various derivatives were dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM. Aliquots from these stocks were added directly to differentiation medium to obtain a final concentration of 10 mkM. Control cells were incubated with the same volumes of DMSO without the inhibitors. The growth medium was replaced, and fresh inhibitors were added every 24 h. Preparation of lysates of L8 cells was performed as described previously. For monitoring myogenin induction, 40 mkg of lysates were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose and probed with anti-myogenin monoclonal antibodies.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TBU7UTV30Q
Created by
admin on Sat Dec 16 07:59:47 GMT 2023 , Edited by admin on Sat Dec 16 07:59:47 GMT 2023
|
PRIMARY | |||
|
DTXSID20360557
Created by
admin on Sat Dec 16 07:59:47 GMT 2023 , Edited by admin on Sat Dec 16 07:59:47 GMT 2023
|
PRIMARY | |||
|
349087-34-9
Created by
admin on Sat Dec 16 07:59:47 GMT 2023 , Edited by admin on Sat Dec 16 07:59:47 GMT 2023
|
PRIMARY | |||
|
1126109
Created by
admin on Sat Dec 16 07:59:47 GMT 2023 , Edited by admin on Sat Dec 16 07:59:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY